HPV16 seropositivity relatively common prior to diagnosis of anal cancer
the ONA take:
According to a new study published online in the Journal of Clinical Oncology, researchers from the National Cancer Institute in Bethesda, Maryland, have found that human papillomavirus (HPV) type 16 (HPV16) seropositivity is relatively common in people prior to receiving a diagnosis of anal cancer.
Because the European Prospective Investigation Into Cancer and Nutrition Study found that HPV16 E6 seropositivity was present in people more than 10 years prior to being diagnosed with oropharyngeal cancer, researchers sought to investigate the extent to which HPV16 E6 seropositivity was present before the diagnosis of anogenital cancers.
Researchers identified 400 cases of anogenital cancers and 718 matched control in which prediagnostic blood samples were available. Results showed that 29.2% of those who later developed anal cancer had HPV16 E6 seropositivity compared with 0.6% of controls (OR = 75.9).
HPV16 E6 seropositivity was less common in patients who later developed cervical, penilee, vaginal, and vulvar cancers. HPV16 E6 seropositivity was more common in blood samples drawn closer in time to diagnosis.
HPV16 seropositivity is relatively common in people prior to receiving a diagnosis of anal cancer.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|